-
ETER100 Study Showcased at ESMO Late-Breaking Abstract Session: Dr. Xinan Sheng Shares New Advances in Targeted and Immunotherapy
Renal cell carcinoma (RCC) is one of the most common malignancies of the urinary system. In recent years, the exploration of combined immunotherapy strategies in RCC has transformed the treatment landscape, making immuno-targeted therapy the global first-line standard for advanced renal cancer. The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in…
-
CUA 2024丨Dr. Xin Yao: ADC Leading the Era of Combined Targeted and Immunotherapy for Advanced Urothelial Cancer
For many years, platinum-based chemotherapy has been the cornerstone of systemic treatment for advanced urothelial cancer, such as bladder cancer. However, the release of clinical research data on antibody-drug conjugates (ADC), such as enfortumab vedotin (EV), has brought new treatment options for patients. During the 31st Urology Academic Conference held recently in Tianjin, Dr. Xin…
-
Dr. Hao Zeng Shares the West China Hospital Team’s Experience in Treating Special Types of Renal Cancer and Clinical Exploration
Renal cancer is one of the three major tumors of the urinary system. Several large phase III studies on combined targeted and immunotherapy have been successful, and the 2024 update of the CSCO renal cancer diagnosis and treatment guidelines has officially brought first-line treatment for advanced renal cancer into the era of combined targeted and…
-
Interview with Dr. Swaminathan P iyer at the EHA 2024: Exploring Breakthroughs in Secondary HLH Treatment with ELA26
At this year’s European Hematology Association (EHA) conference, we had the opportunity to speak with Dr. Swaminathan P iyer, Professor of Medicine at MD Anderson Cancer Center, about the groundbreaking phase I study on ELA26 for secondary hemophagocytic lymphohistiocytosis (HLH). Dr. Iyer shared the promising data from the treatment-naive cohort, which showed a remarkable 100%…
-
-
ESMO 2024丨Dr. Silke Gillessen: Radium-223 Combined with Enzalutamide Offers New Hope for Bone Metastatic mCRPC Patients
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain. Key research in the field of urologic oncology garnered much attention, particularly in the area of prostate cancer. The EORTC-GUCG 1333/PEACE-3 clinical trial (LBA1 – A randomized multicenter open label phase III trial comparing enzalutamide…
-
CSCO 2024 | Dr. Yongmei Yin: A New Era in HER2-Positive Breast Cancer Treatment—From Targeted Therapy to ADC Breakthroughs
With the rapid advancement of medical technology, the treatment of HER2-positive breast cancer has entered a new chapter. In recent years, the emergence of anti-HER2 targeted drugs and new ADC (Antibody-Drug Conjugates) drugs has not only enriched the treatment options but also brought unprecedented hope to patients with HER2-positive breast cancer. At CSCO 2024, Oncology…
-
CUA 2024丨Academician Xu Zhang Shares Conference Highlights and New Advances in Prostate Cancer Radioligand Therapy, and Looks Ahead at the Future Deve
The 31st Urology Academic Conference, organized by the Chinese Medical Association and the Chinese Urological Association (CUA), took place from September 19 to 22, 2024, at the National Convention Center in Tianjin. The conference brought together leading urology experts to showcase the latest clinical research and surgical advancements. After the event, Urology Frontier invited Academician…
Connecting Medical Expertise through Media